Form 4: MoonLake CEO Converts AG Shares to Class A Stock

MoonLake Immunotherapeutics CEO, Jorge Santos da Silva, converted MoonLake AG common shares into 196,316 Class A ordinary shares of the issuer.

Summary

• Jorge Santos da Silva, Chief Executive Officer and Director of MoonLake Immunotherapeutics, reported a change in beneficial ownership.
• On December 19, 2025, Mr. Santos da Silva exchanged 5,836 common shares of MoonLake Immunotherapeutics AG for 196,316 Class A ordinary shares of MoonLake Immunotherapeutics.
• In connection with this exchange, 196,316 Class C ordinary shares of MoonLake Immunotherapeutics were automatically cancelled for no consideration.
• Following this transaction, Mr. Santos da Silva directly beneficially owns 3,074,893 Class A ordinary shares and 0 Class C ordinary shares.
• The exchange rate for MoonLake AG common shares to Class A ordinary shares is approximately 1 common share for 33.638698 Class A ordinary shares, rounded to the nearest whole share.
• Details on vesting conditions for 10,000 'second leaver shares' of MoonLake AG were also provided, with 25% vested on January 18, 2023, and the remaining 75% vesting monthly until fully vested on January 18, 2026.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine conversion, not a sale, and increases the CEO's direct ownership in the publicly traded entity, which can be seen as a positive alignment of interests. No new negative information is presented regarding company performance or strategy.

Positives

• The CEO's conversion of MoonLake AG shares into Class A ordinary shares of the publicly traded entity increases his direct ownership, aligning his interests more closely with public shareholders.

Risks

• Vesting conditions for 10,000 'second leaver shares' of MoonLake AG include an option for MoonLake AG or a designated third party to purchase unvested shares at a nominal value of CHF 0.10 per share if the holder's employment is terminated (for any reason), which could impact the CEO's equity stake under such circumstances.

Future Outlook

The filing primarily reports a past insider transaction and existing equity vesting conditions. It does not provide forward-looking statements or guidance regarding the company's operational performance, financial projections, or strategic outlook.

Industry Context

This Form 4 filing details a routine insider ownership change, specifically an equity conversion, which is common in companies with complex corporate structures involving subsidiaries or pre-IPO equity arrangements. It reflects a simplification of the CEO's equity structure within the publicly traded entity, aligning his holdings more directly with the listed shares.

Comparison to Industry Standards

• This is a standard Form 4 filing, which is a mandatory disclosure for insiders reporting changes in beneficial ownership.
• The mechanism of converting shares from a subsidiary (MoonLake AG) into the parent company's publicly traded shares (MLTX) is a common practice for consolidating and simplifying executive equity interests, particularly following an IPO or a SPAC merger.

Stakeholder Impact

• Shareholders: The CEO's increased direct ownership of Class A ordinary shares aligns his financial interests more closely with those of public shareholders.
• Employees: The detailed vesting conditions for 'second leaver shares' highlight standard executive compensation structures and potential implications for equity upon employment termination.

Next Steps

• Continued vesting of the remaining 'second leaver shares' of MoonLake AG until full vesting on January 18, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider share conversion by the CEO, Jorge Santos da Silva, exchanging shares of MoonLake AG for Class A ordinary shares of MoonLake Immunotherapeutics. This action increases his direct beneficial ownership in the publicly traded entity, which is generally viewed as a positive for aligning management and shareholder interests. However, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell based solely on this ownership change.

Keywords

MoonLake Immunotherapeutics, MLTX, SEC Form 4, Insider Transaction, Share Conversion, Beneficial Ownership, CEO, Equity, Vesting